Intensity Therapeutics (INTS) Return on Capital Employed (2023 - 2026)
Intensity Therapeutics' (INTS) quarterly Return on Capital Employed came in at 101.37% in Q1 2026, up 107516.0% YoY from N/an in Q1 2025, and up 17.89% on a QoQ basis from 123.46% in Q4 2025.
Intensity Therapeutics (INTS) Return on Capital Employed (2023 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 4 years of Return on Capital Employed data on file, last reported at 101.37% in Q1 2026.
- Quarterly Return on Capital Employed rose 107516.0% year-over-year to 101.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 101.37% (up 107516.0% YoY) and the FY2025 annual result came in at 164.09%, up 1455.0% from the prior year.
- Return on Capital Employed rose to 101.37% in Q1 2026, from 123.46% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 38.34% in Q3 2023 to a low of 1176.53% in Q1 2025.
- A 4-year average of 340.82% and a median of 213.39% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 108079 bps — and 2026, when it surged 107516 bps.
- Tracing INTS's Return on Capital Employed over 4 years: stood at 63.51% in 2023, then plunged by 705 bps to 511.41% in 2024, then soared by 76 bps to 123.46% in 2025, then climbed by 18 bps to 101.37% in 2026.
- The last three Return on Capital Employed figures came in at 101.37% (Q1 2026), 123.46% (Q4 2025), and 254.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | -118.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -118.86% |
| Mar 31, 2026 | -101.37% |
| Dec 31, 2025 | -123.46% |
| Sep 30, 2025 | -254.01% |
| Jun 30, 2025 | -809.56% |
| Mar 31, 2025 | -1,176.53% |
| Dec 31, 2024 | -511.41% |
| Sep 30, 2024 | -361.74% |
| Jun 30, 2024 | -213.39% |
| Mar 31, 2024 | -95.74% |
| Dec 31, 2023 | -63.51% |
| Sep 30, 2023 | -38.34% |